(Reuters) – The U.S Senate Committee on Health, Education, Labor, and Pensions said on Friday that Novo Nordisk CEO Lars Jorgensen has agreed to testify voluntarily in a September hearing focusing on U.S. prices for weight loss drugs Ozempic and Wegovy.
(Reporting by Puyaan Singh in Bengaluru)
Comments